ホーム » IVT RNA合成サービス » カタログRNA＆LNP製品 » MAD7 mRNA (Cap1, m1Ψ)
MAD7 MRNA (Cap1, M1Ψ)

MAD7 MRNA (Cap1, M1Ψ)

Editing efficiency of MAD7 on DNMT target using different guides.

MAD7 mRNA (Cap1, m1Ψ)

MAD7 is a novel nuclease that was released by Inscripta in 2017. This nuclease only requires a crRNA for gene editing and allows for specific targeting of AT rich regions of the genome. MAD7 cleaves DNA with a staggered cut as compared to S. pyogenes which has blunt cutting.
RP-A00055
¥63,000.00

Ask us a question
Description

MAD7 is a novel nuclease that was released by Inscripta in 2017. This nuclease only requires a crRNA for gene editing and allows for specific targeting of AT rich regions of the genome. MAD7 cleaves DNA with a staggered cut as compared to S. pyogenes which has blunt cutting.  
 
This mRNA features: 
- A Cap 1 structure with high capping efficiency 
- Codon optimized using GenScript X5 algorithm to enhance expression efficiency 
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) for improved protein expression and reduced innate immune response 
- GenScript’s patented UTR to enhance translation 
- A 100A poly(A) tail to mimic natural mature mRNA
Properties
Form Liquid
Concentration 1mg/mL
Full mRNA length 4153 nt
Full mRNA Molecular Weight 1.34×10^6 Da
Storage buffer 1mM Sodium citrate, pH 6.5
Storage condition Store at -20°C for short term (<3 months), store at -80°C for long term.

Quality Control Specifications
Appearance Clear and free of foreign particles
RNA Length Expected size band detected
RNA Content Target ± 5%
Integrity ≥ 75%
OD260/OD280 1.70 ~ 2.30
Capping Efficiency ≥ 90%
Endotoxin < 10 EU/mg
pH Target ± 0.5

Applications
Transfect 2μg of MAD7 mRNA and 0.4μg of guide RNA into 5×104 HEK293T cells through Lipofectamine™ MessengerMAX™ (or equivalent). 48-72 hours after transfection, extract genomic DNA, and amplify the target region by PCR. Analyze the PCR products through NGS sequencing.

Examples
  • MAD7 MRNA (Cap1, M1Ψ)
    • MAD7 MRNA (Cap1, M1Ψ)

  • MAD7 MRNA (Cap1, M1Ψ)
    • MAD7 MRNA (Cap1, M1Ψ)

    Editing efficiency of MAD7 on DNMT target using different guides.


For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.